Theise Neil D
Beth Israel Medical Center, Division of Digestive Diseases, 1st Avenue at 16th Street, New York, NY 10003, USA.
Expert Opin Biol Ther. 2003 Jun;3(3):403-8. doi: 10.1517/14712598.3.3.403.
It is now understood that there are three cell compartments which physiologically contribute to vertebrate liver parenchymal maintenance and regeneration after injury: mature liver cells (hepatocytes, cholangiocytes), intraorgan stem/progenitor cells (cells of the proximal biliary tree, periductal cells) and extraorgan stem cells (from the circulation and the bone marrow). All of these cell populations, as well as other, non-physiologic stem cells (e.g., mesenchymal stromal cells from the bone marrow, fetal hepatoblasts, embryonic stem [ES] cells), may be used therapeutically for treatment of inherited and acquired liver diseases. This article will summarise our current understanding of these various cell populations, and review possible approaches to their therapeutic use, including cell transplantation, bioartificial liver devices (BLDs), gene therapy and administration of exogenous factors to stimulate normal physiological responses to repair.
现在已经清楚,有三个细胞区室在生理上有助于脊椎动物肝脏实质损伤后的维持和再生:成熟肝细胞(肝细胞、胆管细胞)、肝内干细胞/祖细胞(近端胆管树细胞、导管周围细胞)和肝外干细胞(来自循环系统和骨髓)。所有这些细胞群体,以及其他非生理性干细胞(例如来自骨髓的间充质基质细胞、胎儿肝母细胞、胚胎干细胞[ES]),都可用于治疗遗传性和获得性肝病。本文将总结我们目前对这些不同细胞群体的认识,并综述其治疗应用的可能方法,包括细胞移植、生物人工肝装置(BLD)、基因治疗以及给予外源性因子以刺激正常的生理修复反应。